Abstract
Background
Gastroesophageal reflux disease (GERD) is a common disorder, and is typically treated with proton-pump inhibitors (PPIs) as the recommended first-line therapy. Recently, a new potassium-competitive acid blocker, vonoprazan, was launched in Japan. It is uncertain whether the standard dose of vonoprazan 20 mg is superior to that of PPIs for GERD, so a direct comparison of the therapeutic effects and adverse events between vonoprazan 20 mg and PPIs is needed.
Methods
MEDLINE, the Cochrane Central Register of Controlled Trials, and Embase were chosen as the literature sources. Randomized controlled trials for vonoprazan 20 mg and PPIs published in English were searched. Data from studies meeting the eligibility criteria were extracted individually by two researchers and compared to maintain consistency.
Results
Fifty-six articles were identified in the databases, and one study was manually searched and added to the analysis, ultimately yielding six eligible studies. For the main analysis, the risk ratios (RR) of efficacy and adverse events between vonoprazan and PPIs were 1.06 (0.99–1.13) and 1.08 (0.96–1.22), respectively. Subgroup analysis for patients with severe esophagitis at baseline showed significantly higher results for vonoprazan than lansoprazole, with an RR of 1.14 (1.06–1.22).
Conclusions
Our findings suggest that vonoprazan is non-inferior to PPIs as therapy for patients with GERD. Subgroup analysis indicates that vonoprazan is more effective than PPIs for patients with severe erosive esophagitis. The safety outcomes for vonoprazan are similar to those for PPIs.
Similar content being viewed by others
Abbreviations
- GERD:
-
Gastroesophageal reflux disease
- NERD:
-
Non-erosive reflux disease
- EO:
-
Erosive esophagitis
- VO:
-
Vonoprazan
- RR:
-
Risk ratio
- PPI:
-
Proton-pump inhibitors
- CI:
-
Confidence interval
- P-CAB:
-
Potassium-competitive acid blocker
References
Savarino E, De BN, De CC, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus.. 2017;30:1–9.
El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-esophageal reflux disease: a systematic review. Gut.. 2014;63:871–880.
Triantos C, Koukias N, Karamanolis G, et al. Changes in the esophageal mucosa of patients with non erosive reflux disease: how far have we gone? World J. Gastroenterol.. 2015;21:5762–5767.
Yadlapati R, Dakhoul L, Pandolfino JE, et al. The quality of care for gastroesophageal reflux disease. Dig. Dis. Sci.. 2017;62:569–576. https://doi.org/10.1007/s10620-016-4409-6
Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol.. 2016;51:751–767.
Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol.. 2013;108:308–328.
Freedberg D, Kim LS, Yang Y-X. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology.. 2017;152:706–715.
Strand DS, Kim D, Peura D. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver.. 2017;11:27–37.
Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Ther Adv Gastroenterol.. 2018;11:1756283X17745776.
Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)1H-pyrrol-3-yl]-n-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther.. 2010;335:231–238.
Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther.. 2011;337:797–804.
Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol.. 2011;81:1145–1151.
Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium competitive acid blocker of the gastric H, K-atPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3ylsulfonyl)-1H-pyrrol-3-yl]-n-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther.. 2011;339:412–420.
Miwa H, Igarashi A, Teng L, et al. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. J Gastroenterol.. 2019;54:718–729.
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. version 5.1.0.2011. www.handbook.cochrane.org. Retrieved June 4, 2018.
Liberati A, Altman DG, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Int Med.. 2009;151:65.
Sakurai K, Suda H, Fujie S, et al. Correction to: Short-term symptomatic relief in gastroesophageal reflux disease: a comparative study of esomeprazole and vonoprazan. Dig Dis Sci.. 2019;64:1724. https://doi.org/10.1007/s10620-019-5464-6.
Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther.. 2019;49(2):140–146.
Xiao YL, Zhang ST, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut.. 2019;69:224–230.
Ashida K, Iwakiri K, Hiramatsu N, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol.. 2018;24:1550–1561.
Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther.. 2016;43(2):240–251.
Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther.. 2015;42(6):685–695.
Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp.. 2016;81–82:1–7.
Garnock-Jones KP. Vonoprazan: first global approval. Drugs.. 2015;75:439–443.
Okuyama M, Nakahara K, Iwakura N, et al. Factors associated with potassium-competitive acid blocker non-response in patients with proton pump inhibitor-refractory gastroesophageal reflux disease. Digestion.. 2017;95(4):281–287.
Yang XX, Li YY, Sun YY, et al. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci.. 2018;63:302–311. https://doi.org/10.1007/s10620-017-4866-6
Miyazaki H, Igarashi A, Takeuchi T, et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. J Gastroenterol Hepatol.. 2019;34:1316–1328.
Shimatani T, Sugimoto M, Nishino M, et al. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring. J Gastroenterol Hepatol.. 2012;27:899–906.
Chen LX, Chen YJ, Li B. The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. Sci Rep.. 2016;6:32126.
Sachs G, Shin JM, Munson K, et al. Gastric acid-dependent diseases: a twentieth-century revolution. Dig Dis Sci.. 2014;59(7):1358–1369. https://doi.org/10.1007/s10620-014-3104-8
Kung Y-M, Hsu W-H, Wu M-C, et al. Recent advances in the pharmacological management of gastroesophageal reflux disease. Dig Dis Sci.. 2017;62:3298–3316. https://doi.org/10.1007/s10620-017-4830-5
Jang S-H, Ryu H-S, Choi S-C, et al. Psychological factors influence the gastroesophageal reflux disease (GERD) and their effect on quality of life among firefighters in South Korea. Int J Occup Environ Health.. 2016;22:315–320.
Funding
Funding was provided by the National Outstanding Youth Science Fund Project of the National Natural Science Foundation of China (Grant No. 81803907) and Beijing Science and Technology Plan Project (Grant No. Z171100001717021).
Author information
Authors and Affiliations
Contributions
YC, JL-L, and XT performed the data screening and data collection; CE-X, XH-L performed the statistical analysis; YC, JL-L, XT, QQ-L, FS-K, YD and HJ performed data interpretation; YC and JL-L drafted the manuscript; YC, JL-L and JX-L edited the manuscript for intellectual content; JX-L supervised the project. All authors provided final approval of the submitted manuscript. YC and L-JL planned and designed the research; YC, XT and L-JL collected and analyzed the data; YC wrote the paper; all authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cheng, Y., Liu, J., Tan, X. et al. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci 66, 19–28 (2021). https://doi.org/10.1007/s10620-020-06141-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-020-06141-5